By Kathleen P. Wolff, MBA Specialty Pharma Journal Forging a pathway of innovation is typically easier with friends and allies. But these days, in the world of biosimilars, where stakeholders are still sizing each other up, allies are scarce. At the Biosimilars 20/20 conference in Philadelphia, the consensus among key opinion …
Tag Archives: Steve Miller
June, 2015
April, 2015
-
7 April
CMS Guidance on Biosimilar Reimbursement is One of Many Expected in 2015
By Kathleen P. Wolff, MBA On Mar. 30, 2015, the Centers for Medicare & Medicaid Services (CMS) issued important new guidance on biosimilar reimbursement. Not only was the guidance itself noteworthy, it comes less than a month from the decision to approve the first biosimilar in the U.S. and is …